Health & Fitness
Wed, February 1, 2012
NEW YORK--([ BUSINESS WIRE ])--MURRAY FRANK LLP is investigating claims of breach of fiduciary duties by certain members of the board of directors of Illumina, Inc. (NASDAQ: ILMN) (aIlluminaa or the aCompanya) in relation to the proposed acquisition of the Company by Roche Holding AG (aRochea).
On January 25, 2012, Roche announced that it had offered $5.7 billion in a bid to acquire Illumina, in an all-cash transaction under which Illumina stockholders would receive $44.50 in exchange for each share of Illumina common stock owned. The offer represents a premium of 18% over the closing price of Illuminaas stock on January 24, 2012, and a 64% premium over the closing price of Illuminaas stock on December 21, 2011 a" the day before market rumors about a potential transaction between Roche and Illumina drove Illuminaas stock significantly higher.
The investigation focuses on whether certain members of Illuminaas board of directors breached their fiduciary duties in connection with Rocheas proposed acquisition of the Company by refusing to enter into negotiations regarding Rocheas offer to acquire the Company well above its market price.
If you are a current investor in Illumina, who purchased ILMN shares before January 25, 2012, and you wish to discuss this investigation or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Bridget V. Hamill at (800) 497-8076 or (212) 682-1818, or by email at [ investigations@murrayfrank.com ].
